<DOC>
	<DOCNO>NCT02166437</DOCNO>
	<brief_summary>In study , investigator would like analyze bone mineral density ( BMD ) , bone turnover maker , fracture prevention effect bisphosphonate denosumab randomly divide follow daily teriparatide Japanese patient clinical practice . The participant treat investigator hospital , severe osteoporotic condition .</brief_summary>
	<brief_title>Clinical Results Bisphosphonate Denosumab Therapy Following Teriparatide Therapy Japanese</brief_title>
	<detailed_description>Registry criterion : Patients treat investigator hospital use teriparatide . Enrolled patient severe osteoporosis ; two previous osteoporotic fracture , low BMD ( &lt; young adult mean 65 % ) . Interventions : blood analyse dual-energy X-ray absorptiometry ( DXA ) every 4 month Informed consent : Written inform consent obtain . Sample size : Five-hundreds participant</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>severe osteoporotic patient cancer , hypercalcemia , etc ( i.e . patient could use bisphosphonate , denosmab , teriparatide )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>BMD</keyword>
	<keyword>teriparatide</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>denosmab</keyword>
</DOC>